SS-31 Peptide: Evidence, Safety, Dosing Questions, and Access

SS-31, also called elamipretide, Bendavia, or MTP-131, is a mitochondria-targeting tetrapeptide studied in conditions such as primary mitochondrial myopathy, Barth syndrome, heart failure, and STEMI-related reperfusion injury 1 2 4 9. Its evidence grade is A, meaning two or more human randomized trials exist in the indexed search summarized below 12. We have not verified FDA approval for these uses. That does not prove benefit or safety. Chia does not offer SS-31.

What it is

SS-31 is a peptide also called elamipretide, Bendavia, or MTP-131. In the supplied human literature, it appears in studies of primary mitochondrial myopathy, Barth syndrome, heart failure, and reperfusion injury after ST-segment elevation myocardial infarction, or STEMI 1 2 4 9.

The generic INN name is elamipretide. The drug class is often described as a mitochondria-targeting peptide, meaning it is being studied for effects tied to mitochondria, the parts of cells that help make usable energy 9.

Names to know

• SS-31: the research name many people search online.
• Elamipretide: the generic INN name used in many clinical studies.
• Bendavia: a development name used in cardiovascular research.
• MTP-131: another development name used in the EMBRACE STEMI trial 4.

For related mitochondrial and longevity education, Chia also covers MOTS-c, rapamycin, and the broader biology of mitochondrial fusion. Those pages are separate topics; their evidence should not be treated as evidence for SS-31.

Mechanism of action

Elamipretide has been described in human cardiovascular research as a novel mitochondria-targeting peptide 9. In plain English, the proposed idea is that a peptide aimed at mitochondria may affect cell-energy stress pathways, but the supplied records do not prove a single patient-facing benefit from mechanism alone.

Mitochondria-targeting peptide mechanism

Mitochondria are central to how cells handle energy demand. That is why SS-31 has been studied in diseases where energy production or heart-muscle stress is part of the clinical question, including primary mitochondrial myopathy and heart failure 2 9.

What mechanism evidence can and cannot prove

A mechanism is not the same as a clinical result. The supplied records support saying SS-31 has been studied in human trials, but they do not support using it as a general longevity, athletic, or weight-loss peptide for healthy people 2 4 9.

Evidence

SS-31 has an assigned evidence grade of A. That grade is based on the quantity and design of indexed human trials, not on a guarantee that the compound works or is safe.

In primary mitochondrial myopathy, elamipretide has been studied in a randomized dose-escalation trial, a randomized crossover trial, and the MMPOWER-3 randomized clinical trial 5 7 2. A post hoc analysis of MMPOWER-3 looked at genotype-specific effects, which should be read as exploratory rather than definitive 3.

In Barth syndrome, the supplied records include a long-term open-label extension and a natural-history comparison study 8 6. Open-label and natural-history designs can be useful, especially in rare diseases, but they are more limited than blinded randomized trials because expectations, selection, and comparison methods can affect results.

In cardiovascular research, elamipretide was studied in a randomized, placebo-controlled heart-failure trial, and MTP-131 was studied in the EMBRACE STEMI phase 2a trial for safety, tolerability, and reperfusion-injury questions in patients undergoing primary percutaneous coronary intervention 9 4. A related EMBRACE STEMI analysis evaluated the relation of left ventricular mass and infarct size in anterior-wall STEMI 10.

Why an A grade means trial quantity, not proven benefit

The important nuance is that an evidence grade can describe study design without settling the medical question. A compound may have several randomized trials and still have uncertain use, mixed results, narrow disease-specific relevance, or safety questions that matter for an individual patient 2 5 7.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.

Reported dosing ranges

Studied dosing is not dosing advice. The supplied records confirm that elamipretide dosing was studied in human trials, including a randomized dose-escalation trial and randomized crossover trial in adults with primary mitochondrial myopathy, but the retrieved citation data provided to us does not include numeric dose ranges 5 7.

Because the supplied record set does not include numeric dosing details, this page does not list numbers. That is intentional: guessing a dose would be less useful, and less safe, than saying the available citation text is incomplete.

Legal status

Our regulatory log holds no confirmed federal action for SS-31. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.

Safety

Safety data for SS-31 come from specific study populations, not from broad consumer use. The supplied records include randomized trials and longer-term follow-up that evaluated efficacy and safety in primary mitochondrial myopathy and Barth syndrome 2 5 7 8.

The supplied citation text does not list specific adverse-event rates or named side effects. So the most accurate statement is limited: safety was assessed in these studies, but the record set provided here is not enough to name a side-effect profile or to estimate personal risk 2 8.

Why trial safety data may not predict individual risk

Trial safety data depend on who was enrolled, who was excluded, how the compound was made, how it was given, and how patients were monitored. A person with heart disease, a mitochondrial disorder, pregnancy, complex medications, or specialist care needs may face risks that are not answered by a trial title or abstract alone 2 4 9.

Unregulated supply adds a separate risk. A product sold online as “research use only” is not a medical visit, does not replace a prescription, and may not provide the identity, sterility, impurity, storage, or monitoring standards a clinician would expect for patient care.

Interactions

Interaction data are limited in the supplied record set. We do not have a dedicated SS-31 drug-interaction study in the provided sources, so no one should read this as reassurance that interactions do not exist.

Medication history, heart disease, mitochondrial disease, pregnancy, and specialist care

The studied populations include people with primary mitochondrial myopathy, Barth syndrome, heart failure, and STEMI-related care settings 2 4 8 9. That makes medical context important: a clinician would need to review heart history, neurologic or genetic diagnoses, current prescriptions, supplements, allergies, pregnancy status, and specialist treatment plans.

This is especially important because trial eligibility rules are not the same as real life. People outside the studied population may have a different risk-benefit profile than trial participants 2 5 7.

How to obtain it legally

SS-31 access should start with a legitimate medical process, not a shopping search. That process means a licensed clinician reviews the reason for interest, medical history, medications, risks, and whether a prescription pathway is appropriate.

Clinician evaluation and prescription-only care pathways

A real medical evaluation should ask why SS-31 is being considered, whether the goal matches any human evidence, and whether safer or better-studied options fit the patient’s situation. For example, the supplied evidence supports discussion of disease-specific studies, but it does not establish SS-31 for consumer weight loss or general wellness 2 8 9.

Why research-chemical vendors are not medical care

A research-chemical website is not the same thing as a clinician, prescription, or licensed pharmacy. It does not review contraindications, manage side effects, coordinate with specialists, or provide ongoing follow-up.

Chia’s role: education only for SS-31

Chia does not offer SS-31 in our current treatment catalog. We publish education on compounds like SS-31 because patients often see peptides online before they understand the evidence, safety limits, or access questions.

For treatments Chia does offer, care is 100% online: a short health questionnaire, licensed US provider review, prescribing only when clinically appropriate, provider-guided dosing, patient-portal messaging, and shipment from US state-licensed 503A compounding pharmacies. A prescription is never guaranteed, and compounded medications are not FDA-approved. If you are exploring Chia’s current care options, you can start with the eligibility quiz.

Related clinician-guided longevity topics in Chia’s catalog include NAD+, which Chia offers as injection and nasal spray, and Sermorelin, which Chia offers as injection, nasal spray, and tablets. These are different treatments with different evidence questions; they should not be treated as substitutes for SS-31.

If you want a deeper dosing-focused discussion, see our related SS-31 education page on SS-31 peptide dosing and cycle questions.

Keep reading

Peptides

SS-31 Peptide (Elamipretide): What It Is, How It Works, and What the Evidence Shows

Peptides

SS-31 Peptide: What to Know Before You Buy

Longevity

Mitochondrial Peptides: What They Are, What the Evidence Shows, and What Is Still Unknown